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ABSTRACT
Objectives: To compare the costs and cost-
effectiveness of managing patients with uncontrolled
blood pressure (BP) using telemonitoring versus usual
care from the perspective of the National Health Service
(NHS).
Design:Within trial post hoc economic evaluation of
data from a pragmatic randomised controlled trial using
an intention-to-treat approach.
Setting: 20 socioeconomically diverse general practices
in Lothian, Scotland.
Participants: 401 primary care patients aged 29–95 with
uncontrolled daytime ambulatory blood pressure (ABP)
(≥135/85, but <210/135 mm Hg).
Intervention: Participants were centrally randomised to
6 months of a telemonitoring service comprising of
self-monitoring of BP transmitted to a secure website for
review by the attending nurse/doctor and patient, with
optional automated patient decision-support by text/email
(n=200) or usual care (n-201). Randomisation was
undertaken with minimisation for age, sex, family practice,
use of three or more hypertension drugs and
self-monitoring history.
Main outcome measures: Mean difference in total
NHS costs between trial arms and blinded assessment of
mean cost per 1 mm Hg systolic BP point reduced.
Results: Home telemonitoring of BP costs significantly
more than usual care (mean difference per patient
£115.32 (95% CI £83.49 to £146.63; p<0.001)).
Increased costs were due to telemonitoring service costs,
patient training and additional general practitioner and
nurse consultations. The mean cost of systolic BP
reduction was £25.56/mm Hg (95% CI £16.06 to £46.89)
per patient.
Conclusions: Over the 6-month trial period, supported
telemonitoring was more effective at reducing BP than
usual care but also more expensive. If clinical gains are
maintained, these additional costs would be very likely to
be compensated for by reductions in the cost of future
cardiovascular events. Longer-term modelling of costs
and outcomes is required to fully examine the cost-
effectiveness implications.
Trial registration: International Standard Randomised
Controlled Trials, number ISRCTN72614272.
ARTICLE SUMMARY
Article focus
▪ Poor blood pressure (BP) control contributes a
substantial financial burden on the National Health
Service (NHS) via increased risk of stroke and heart
disease; however, it is often difficult to control.
▪ Home telemonitoring offers a potentially attractive
means of overcoming issues leading to poor BP
control such as infrequent monitoring and clinician
and patient reluctance to intensify therapy.
▪ This paper presents a within-trial economic
evaluation from an NHS perspective comparing
the costs and cost-effectiveness of home telemo-
nitoring of BP versus usual care for patients with
uncontrolled BP.
Key messages
▪ Over the 6 months of trial period observed,
home telemonitoring was significantly more
expensive and more effective than usual care at
£25.56/mm Hg reduced/patient.
▪ If clinical gains are maintained, the additional
costs are likely to be compensated for by reduc-
tions in the cost of future cardiovascular events;
however, longer term modelling of costs and
outcomes is required to fully examine this.
Strengths and limitations of this study
▪ The trial benefited from a pragmatic setting,
intention-to-treat analysis, blinding of outcome
assessment and a broad socioeconomic spectrum
of participants.
▪ The main limitations were due to the relatively short
follow-up period of 6 months. This restricted the
potential to examine long-term effects on cardio-
vascular events or estimate outcomes in the pre-
ferred terms of quality adjusted life years.
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INTRODUCTION
Hypertension is a major reversible risk factor for stroke
and heart disease. It was estimated in 2001 that uncon-
trolled high blood pressure (BP) costs $370 billion glo-
bally (£256 billion, €413 billion) with a potential cost of
$3.6 trillion (£2.5 trillion, €4.0 trillion) over a 10-year
period in indirect costs.1 Despite effective medications,
BP is difﬁcult to control for many people.2 This is due
in part to infrequent monitoring,3 a reluctance on the
part of clinicians to intensify treatment4 and pharmaco-
logical interventions by patients.5 Telemonitoring of BP
involves patients regularly taking their own readings with
onward transmission in almost real time to a website
which can be accessed by themselves or by their doctor
or nurse and can provide patients with decision-support,
in terms of when to contact a doctor or nurse for advice,
which is then sent by text or email.
This paper presents a within trial, economic evalu-
ation from the perspective of the National Health
Service (NHS) of data collected during the HITS trial.6
This was a trial of a telemonitoring-based service
redesign compared with usual care for the management
of uncontrolled hypertension which was powered to
detect differences in mean systolic BP but also collected
resource use data as a secondary outcome. The analysis
presented here, while not part of the trial protocol, was
conceived prior to completion of the primary clinical
analysis for the trial.
METHODS
Overview of the HITS trial
This was a 6-month pragmatic, prospective, parallel-group
randomised controlled trial with blinded outcome assess-
ments. In total, 401 patients were recruited from 20 prac-
tices representing a range of socioeconomic diversity
including the ﬁfth most deprived and second most afﬂu-
ent in Lothian, Scotland.
Participants were included in the study if their daytime
ambulatory BP averaged ≥135/85 and <210/135 mm Hg
measured by the Spacelabs 90207 Ambulatory Blood
Pressure Monitor (ABPM).7 Exclusion criteria were the
inability to consent, atrial ﬁbrillation, being on the stroke
or diabetes registers (as these patients would be invited to
other trials in our portfolio of trials investigating the role
of telemonitoring in the management of long-term con-
ditions), treatment for cardiac event or other life-
threatening illness within the past 6 months, major
surgery within the last 3 months, renal failure or hyper-
tension not managed in primary care. A full list of base-
line measurements can be found in table 1.
Patients were randomised in a 1:1 ratio either to the
telemonitoring intervention or usual care using a secure
randomisation system provided by the Edinburgh
Clinical Trials Unit with minimisation on the basis of
age, sex, family practice, use of three or more hyperten-
sion drugs and self-monitoring history. As simple mini-
misation within centres can lead to the alternation of
treatment allocation and potential loss of allocation con-
cealment, a degree of random allocation was also
incorporated.
Research nurses gave patients assigned to the interven-
tion a training session on how to use the telemonitoring
equipment. As the intervention comprised providing
telemetric equipment, neither the participants nor the
investigators could be masked to group assignment.
Participants were asked to monitor their own BP twice
each morning and twice each evening for the ﬁrst week
and then at least weekly thereafter or as often as they
wished. They used a validated automated sphygmoman-
ometer (Stabil-O-Graph mobil, IEM, Germany).8 This
linked via Bluetooth connection to a mobile phone,
which automatically transmitted readings to a central
server managed by IEM Ltd (Stuttgart, Germany).
Patients and clinicians could log on to a website to see
the data and automated SMS texts/emails could be sent
to patients informing them of the level of their control
(see box 1 for a fuller description of the process).
Patients could contact clinicians if they were concerned
about their BP control and clinicians could contact
patients if needed to arrange modiﬁcation of therapy
where required. The target home-monitored BP was
<135/85 mm Hg based on the contemporaneous UK
guidelines,9 subsequently endorsed by the National
Institute for Health and Clinical Excellence (NICE).10
Patients allocated to the usual care arm were told that
the ABPM showed that their BP was uncontrolled
and that they should see their general practitioner
(GP)/practice nurse for further management, otherwise
they should receive standard care for hypertension from
their GP or nurse who were asked to aim for a target
surgery BP of <140/90 mm Hg based on UK guidelines
(current at the time).9
In order to maintain blinding of outcome assessment,
the patients were asked not to reveal their treatment
group allocation to the research nurse undertaking the
assessment; however, it is not possible to rule out
unblinding where the patients did not adhere to this.
Cost estimation
Mean costs per patient were estimated from an NHS per-
spective. The trial collected the data of the number of
consultations with a GP, practice nurse or district nurse
(separately for practice, telephone or home visits),
NHS24 (emergency out-of-hours telephone helpline)
contacts, out-of-ofﬁce consultations with the Lothian
Unscheduled Care Service and accident and emergency
visits. These were collected at follow-up by a research
nurse with access to patient records. If the patient did
not attend the follow-up, but agreed for the data to be
collected, the research nurses completed the data from
the records in their absence. Data on each drug issued
to each patient, the dose per day and the number of
days issued were taken from GP records from randomisa-
tion until 6 months after randomisation. Drugs were
assumed to be the lowest cost generic treatment which
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Table 1 Baseline characteristics for full dataset
Variable Monitored (N=200) Control (N=201)
Age (years) mean (SD) 60.5 (11.8) 60.8 (10.7)
Male N (%) 117 (58.5) 120 (59.7)
Blood pressure self-monitoring history N (%)
Never 128 (64.0) 126 (62.7)
Occasionally 56 (28.0) 56 (27.9)
Regularly 16 (8.0) 19 (9.5)
Body mass index (kg/m2) mean (SD) 30.1 (5.7) 30.2 (6.2)
Smoking N (%)
Yes 23 (11.5) 20 (10.0)
Mean (SD) (cigarettes/day) 17.6 (9.2) 14.9 (10.4)
No 177 (88.5) 181 (90.0)
Alcohol use* N (%)
Yes 158 (79.0) 159 (79.1)
Median (first, third quartile)(units of alcohol(10 ml)/day) 1.7 (0.9, 2.9) 2.0 (0.7, 4.0)
No 37 (18.5) 41 (20.4)
Exhaled carbon monoxide category N (%)
Non-smoker (1–6) 177 (88.5) 179 (89.1)
Light smoker (7–10) 0 (0.0) 3 (1.5)
Moderate smoker (11–20) 8 (4.0) 11 (5.5)
Heavy smoker (20+) 15 (7.5) 8 (4.0)
Cholesterol level (mmol/l)† mean (SD) 5.5 (1.0) 5.3 (1.0)
HbA1c level (mmol/mol)‡ mean (SD) 37.7 (6.5) 37.7 (5.4)
Urinary sodium/creatine ratio§ mean (SD) 9.7 (5.4) 10.9 (8.7)
Surgery measured systolic BP (mm Hg) mean (SD) 152.9 (15.1) 152.4 (14.3)
Surgery measured diastolic BP (mm Hg) mean (SD) 92.1 (11.5) 89.9 (11.3)
Daytime ambulatory systolic BP (mm Hg) mean (SD) 146.2 (10.6) 146.2 (10.5)
Daytime ambulatory diastolic BP (mm Hg) mean (SD) 87.1 (10.0) 85.4 (9.6)
HADS29 anxiety score¶ mean (SD) 5.0 (2.9) 5.1 (3.6)
HADS depression score¶ mean (SD) 2.8 (2.4) 2.9 (2.5)
Exercise tolerance score35** mean (SD) 7.8 (2.9) 7.6 (3.0)
Stanford self efficacy questionnaire (short version)36††
Mean (SD) 8.7 (1.4) 8.5 (1.4)
Morisky medication adherence scale37 N (%)
Sometimes forgets to take medication‡‡
Yes 61 (30.5) 63 (31.3)
No 132 (66.0) 132 (65.7)
Sometimes careless about taking medication§§
Yes 24 (12.0) 23 (11.4)
No 169 (84.5) 173 (86.1)
Sometimes stops taking medication when feels better¶¶
Yes 11 (5.5) 15 (7.5)
No 181 (90.5) 180 (89.6)
Sometimes stops taking medication when feels worse***
Yes 18 (9.0) 22 (10.9)
No 170 (85.0) 173 (86.1)
Number of defined daily doses of hypertension drugs
Median (first, third quartile) 1.5 (1, 3) 1.7 (1, 3)
EuroQol-5D23††† mean (SD) 0.875 (0.177) 0.857 (0.220)
Missing data.
*Five in monitored and one in control group.
†Five in monitored and eight in control group.
‡Seven in monitored and nine in control group.
§Four in monitored and two in control group.
¶Two missing in each group.
**One in monitored and two in control group.
††Six in monitored and one in control group.
‡‡Six in monitored and seven in control group.
§§Five in monitored and seven in control.
¶¶Six in monitored and eight in control.
***Six in monitored and 12 in control group.
†††Five in monitored and six in control group.
HADS, hospital anxiety and depression scale.
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matched the daily dosing structure recommended in the
British National Formulary11 unless a speciﬁc brand was
stated. Assumptions were made on an ad hoc basis
blind-to-treatment allocation for the 2.4% of drug
entries where doses and drug combinations failed to
match perfectly to the recommended dosing structure.
Unit costs were applied to each item. Where possible,
these were taken from recognised national sources.12–18
The base year for costs was the ﬁnancial year 2009/2010.
Any estimates from different years were inﬂated/deﬂated
using an appropriate inﬂation index (see table 2). With
the exception of equipment costs (see table 3), discount-
ing was not required as the trial was less than 1 year in
duration.
A detailed breakdown of the interventions costs of
6 months of BP telemonitoring, assumptions made in
their estimation, price weights applied, inﬂation indices
used and their sources is given in table 3. The price of
the full 6 months of intervention was applied uniformly
to all patients in the monitored group, regardless of
whether or not they completed the trial.
Although data were also collected on the number of hos-
pital admissions attended by each patient during the trial,
the cost of hospital admissions can vary substantially
depending on the nature of the admission15 19 and speciﬁc
details of the nature of each admission were not recorded.
Instead, reported admissions were matched with entries in
the adverse events log for the trial to generate verbal
descriptions of each event. BM viewed the extracted
descriptions of each event blind-to-randomisation alloca-
tion, assigned Healthcare Resource Group (HRG4) codes
based on the descriptions and assessed whether the event
could be at least be possibly related to BP management.
HRG4 codes are used in the NHS to group procedures
into categories of hospital care which incur similar
resource use.
Of the 28 admissions recorded in the adverse events
log, 7 (25%) were for cardiovascular-related diagnoses
and as such were deemed indirectly related to high BP
or related to dizziness or falls for which BP could not be
ruled out as a contributing factor. None could speciﬁc-
ally be related to telemonitoring itself. The decision
therefore was made not to include these costs in the
base-case analysis as there was a risk of overwhelming
the more robust estimates of other cost factors with
unreliable, and likely unrelated, admission costs.
Box 1 Description of the telemonitoring intervention (see web supplemental files for illustrations)
The intervention: The practices and participants were asked to use a system which comprised a validated electronic home blood pressure
(BP) monitor and mobile phone technology that enabled the transfer of BP readings via SMS to a secure website which was accessible to
the user and their doctor or nurse, and also provided automated feedback to the patient. The BP monitor linked to a mobile phone wirelessly,
via Bluetooth. The components of the intervention were
Home BP monitoring: Participants were asked to record their BP as agreed with the healthcare team, or more frequently as they wished.
Guidance was initially to record BP twice in the morning and twice in the evening for a week in line with the European guideline on BP mon-
itoring,36 to build a baseline average. Thereafter, they were asked to take weekly measurements preferably at different times of day if their
average BP was within the recommended range; however, if they had made any lifestyle or medication change which would impact on their
BP, they were asked to measure their BP for a more intensive period of monitoring to allow the rolling average to change and to more
quickly assess the effect.
Transmission of data: This simply required the phone to be switched on and to have a signal when the BP measurement was taken.
Participants just had to apply the cuff and press a button on the BP monitor. The reading and transmission occurred automatically. Mobile
phone problems did not lead to the loss of data because all readings were stored in the monitor and any untransmitted readings were sent
when the next reading was taken.
Feedback to patient participants (closed loop feedback): In addition to optionally accessing their BP record on-line, participants could also
opt to receive reports via text message or email. These gave advice on the current status of their BP based on the average of the last 10
readings, and whether they should contact their doctor or nurse. Reports were generated every 10 readings or weekly, whichever was
sooner, with a reminder to check BP if this had not been done. These reports could reassure them that their average BP was within target
(<135/85 mm Hg) or tell them that their BP average was improved on the last report, but not yet to target and to maintain current therapy,
or that their BP was not at target and that they should contact their clinician. If an individual BP reading was very high (>220/120 mm Hg)
an immediate text or email report was generated reinforcing the written advice in the patient information leaflet to rest for 30 min, check
again and contact the practice if BP remained very high.
Sharing the readings with the healthcare team: Members of the healthcare team were able to access the records of their patients online
via a secure login to a summary screen which listed their patients, their average BP over the last 10 readings and the date of their last
reading. Average BPs outside the recommended limits (set at 135/85 mm Hg for the study) were highlighted. Clicking on the each individual
patient led to lists or graphs of all their readings. Clinicians could then check their patients’ electronic general practitioner (GP) record to see
if there had been recent advice regarding medication or lifestyle change and if not, could contact the patient to make a change. Clinicians
were recommended to check the website weekly, but the frequency of log-on could be chosen by them.
Usual care: Participants allocated to the usual care group were asked to continue to attend the practice for BP checks according to the
usual routine of the practice. If they were already home monitoring they were not discouraged from continuing.
All participants: For all participants, the GP/practice nurse were informed that the ambulatory monitoring used to screen for eligibility for
the HITS trial had shown that their average BP was above the target range, but they were not given the actual reading. All participants were
given an information pack containing a range of publicly available leaflets on hypertension management and lifestyle modification.
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However, a sensitivity analysis was undertaken including
the costs of hospital admissions where price weights
were applied from the Scottish National Tariff19 based
on the HRG4 code selected.
Effect variable
The effect variable for the cost-effectiveness analysis was
mean daytime systolic ambulatory blood pressure
(SABP). For both groups, this was measured using a
Spacelabs 90207 ABPM. We therefore calculated the cost
per mm Hg systolic BP reduced over the 6 months inter-
vention period.
Analysis
All analyses were undertaken on an intention-to-treat
basis.
Missing data
Primary outcome data were missing for 11.5% of
patients including 20 participants (6 in the intervention
group and 14 in the usual care group) were either lost
to follow-up or who withdrew consent. Economic vari-
ables were missing for 0–8.7%. In total, 21.9% of
patients had missing data for at least one variable of
interest. Multiple imputation by chained equations20 was
used to create 10 imputed datasets by imputing incom-
plete variables under fully conditional speciﬁcation. This
was based on age, sex, body mass index, BP (systolic and
diastolic), number of hypertension drugs, cholesterol,
exhaled per cent carbon monoxide, blood glycated
haemoglobin (HbA1c), Euroqol-5D (EQ-5D) responses
and all healthcare resource use variables. Calculations
were undertaken in STATA 12 using the ‘mi ice’
command. Normally distributed parameters (including
primary outcome data) were imputed using multiple
regression by ordinary least squares; ordered categorical
variables were imputed using ordinal logistic regression
and other non-normal variables imputed using predict-
ive mean matching. Model parameters were then esti-
mated using the respective regressions techniques
described below. These estimates and their SEs were
combined using Rubin’s rules.21
Cost analysis
Univariate analysis was undertaken of differences
between trial arms in terms of total costs and each cost
subelement. As the cost data were non-normally distribu-
ted with a heavy right skew and long tail, testing was per-
formed using non-parametric bootstrap of differences in
mean patient costs between trial arms and bias corrected
Table 2 Price weights, calculations and sources
Variable Value Unit Source(s)/notes
General
Practitioner
Surgery £36.00 Per Consultation 12
Home £120.00 Per Consultation 12
Phone £22.00 Per Consultation 12
Practice nurse
Surgery £12.00 Per Consultation 12
Home £20.00 Per Consultation 12
Phone £4.74 Per Consultation Cost per hour12×average call length13
District nurse
Surgery £18.86 Per Consultation Cost per hour12×average consultation length.13 Consultation length
assumed to be equal to that of a practice nurse
Home £27.00 Per Consultation 12
Phone £10.46 Per Consultation Cost per hour12×average Call length.13 Call length assumed to be equal
to that of a practice nurse
NHS 24 contact £41.71 Per Contact £35.6914 inflated to 2009/2010 prices using Hospital and Community
Health Services (HCHS) pay and price inflation index12)
LUCS consultation £64.82 Per Consultation Number of LUCS contacts divided by total budget, obtained private
communication with NHS Lothian. Information on cost per consultation
was not available
A&E visit £95.00 Per Visit 15
Medication All medication use recorded was priced individually using the 2011 prices from the MIMS data base16
deflated to 2009 prices using the Pharmaceutical Inflation component of the CPI37 with adjustments
made for 10.5% claw back17 and container costs18
HBPM service and
device
£70.77 For 6 months Per patient (see table 3)
A&E, accident and emergency; HBPM, home blood pressure monitor; LUCS, Lothian Unscheduled Care Service; NHS, National Health
Service.
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CIs and p values (two-tailed) were reported for each cost
item with signiﬁcance set at the 5% level.
Cost-effectiveness analysis
Baseline resource use was not recorded. We would expect
randomisation to balance out baseline costs between
groups. However, to counteract any baseline imbalances,
point estimates for incremental costs were estimated
using a generalised linear model (GLM) controlling for
age, sex, baseline systolic BP and baseline health-related
quality of life (calculated by baseline EQ-5D index
score22). GLMs allow adjustments to be made for hetero-
scedasticity and skew by the adoption of a ‘family’ and
link function.23 24
Family function was selected by Modiﬁed-Parks test24
and a power function for the link was selected on the
balance of p values from three tests of ﬁt as recom-
mended by Glick et al23 These tests were the Modiﬁed
Hosmer & Lemeshow test (tests for systematic bias in ﬁt
on raw scale), the Pregibon link test (tests for linearity
of response on scale of estimation) and Pearson correl-
ation test (tests for systematic bias in ﬁt on raw scale).
The Gaussian family was selected and a power of 0.5343
was selected for the link function.
For incremental BP point reduction, multiple regres-
sion (by ordinary least squares) was used controlling for
baseline SABP and all minimisation variables, namely
age, sex, general practice, use of three or more hyper-
tension drugs and self-monitoring history. This was
selected for its equivalence to the analysis used for the
variable in the primary analysis.6
Incremental cost-effectiveness ratios (ICERs) were
expressed as cost/1 mm Hg systolic BP point reduced.
Bias-corrected CIs25 for the ICERs were estimated from
the bootstrapped data generated using the ‘recycled pre-
dictions’ method as described by Glick et al.23 This tech-
nique generates a large number of bootstrapped samples
(10 000 replications were used). The chosen regressions
for each variable were used to estimate incremental costs,
BP and their respective ICERS within each sample.
The proportion of samples in which the intervention
is shown to be cost-effective to the NHS at a given price
per mean systolic mm Hg (using the net beneﬁt tech-
nique26) is used to estimate the probability that the
intervention is cost-effective at that price. The process
was repeated varying the price over a range of £0 to
£100/systolic mm Hg to plot cost-effectiveness accept-
ability curves (CEACs). CEACs show the probability that
the treatment is cost-effective at varying costs (willing-
ness on behalf of the NHS to pay) per unit of outcome
(1 mm Hg systolic BP reduced) to a decision-maker.
As several assumptions were made in the intervention
costs (see table 3), as a sensitivity analysis, CEACs were
calculated with the total cost of 6 months of intervention
varied in increments of 25% to ± 100% of the base case
price (see ﬁgure 1).
RESULTS
Analysis of costs
Table 4 details the results of the univariate analysis of
costs and resource use per patient associated with each
Table 3 Price estimation and components for cost of intervention over 6 months (per patient)
Variable Value Unit Source(s)/notes
Home blood pressure
monitor (HBPM):
Initial training of
patient in device use
£12.00 Per Patient One off patient training in use of device. Priced as an assumed
20 min of practice nurse time (£36/h client contact12) based on the
trial’s pilot work
HBPM device £53.11
£1.20 Per
Each
month*
Local pricing from manufacturer invoice (60 Euro converted to GBP
using average exchange rate 2009/201038)
Mobile phone £48.48
£1.44 Per
Each
month*
Local pricing from internal communications with NHS Lothian
telecoms (£49)) deflated from 2011 prices to 2009/2010 using
medical products component of CPI37
Server hosting £0.42 Per Month Local pricing from Supplier Invoice (£1000/year for all patients,
divided by 200 patients over 12 months)
Web hosting £2.59 Per Month Local pricing from Supplier Invoice (3.10 Euro converted to GBP
using average exchange rate 2009/201038)
Sim card £1.98 Per Month Local pricing from internal communications with NHS Lothian
telecoms (£2 deflated from 2011 prices to 2009/2010 using medical
products component of CPI37)
Nurse time £2.17 Per Month Assumption of 1 min/week of practice Nurse time spent checking
incoming HBPM data (£30/h non-specific work12) based on
anecdotal information
Total† £70.77 For 6 months
*Per month costs of HBPM device and mobile phone calculated using the annuity method39 at a discount rate of 3.5%/year as recommended
by NICE.34 Assumed lifespan of device: 4 years, assumed life of mobile phone: 3 years.
†Total does not match sum of components due to rounding of values.
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trial arm. The mean total estimated healthcare cost per
patient was £287.18 in the intervention group and
£177.95 in the usual care group (mean difference
£109.23, 95% CI £76.36 to £140.63) in univariate ana-
lysis. Controlling for baseline characteristics in the multi-
variate analysis gave similar results with a mean total
costs of £290.13 in the intervention group and £174.81
in the usual care group (mean difference £115.32, 95%
CI £83.49 to £146.63).
The difference in total costs remained signiﬁcant with
the cost of the telemonitoring technology excluded
from the analysis demonstrating that NHS costs rose
outside of the cost of the intervention itself. This was
driven largely by a signiﬁcant increase in mean costs
arising from approximately one additional GP surgery
consultation and half a practice nurse surgery consult-
ation per person in the intervention group compared
with the usual care group. The only other signiﬁcant
cost element difference was approximately half an add-
itional practice nurse phone consultation. No other cost
element was signiﬁcantly different between the groups.
This included the cost of the prescribed medication.
Despite a signiﬁcantly greater increase in the doses of
the prescribed medication in the telemonitored group
over that of the usual care group,6 the rise in cost was
relatively trivial as often higher strength medications
were priced similarly to lower strengths.
In sensitivity analysis, the mean cost of hospital admis-
sions in the intervention arm was £287.01 compared
with £181.54 in the control arm (mean difference
£105.47, 95% CI £−123.16 to £402.40; p=0.424) which
raises the mean difference in total NHS costs to £214.70
(95% CI £−23.71 to £526.65; p=0.098). However, this
estimate was dominated by one patient in the interven-
tion arm with admissions costing over £17 000, none of
which were assessed to be possibly related to BP manage-
ment. When the costs of these admissions of this patient
were excluded, the equivalent mean differences in hos-
pital costs fell to £16.56 (95% CI £−188.04 to £202.17;
p=0.846) and total costs to £125.79 (95% CI £−88.85 to
£318.40; p=0.223).
Analysis of BP point reduction
Following imputation, the mean daytime SABP fell in
both groups, from 146.20 to 140.15 mm Hg in the tele-
monitoring arm and 146.22 to 144.50 mm Hg in the
usual care arm. The difference in mean daytime SABP
at 6 months between the two arms (ie, control-
telemonitoring) was 4.51 mm Hg (95% CI 2.49 to 6.61;
p<0.001), adjusted for baseline mean daytime SABP and
minimisation factors.
Cost-effectiveness analysis
Figure 3 shows the joint distribution of incremental costs
and incremental systolic BP point reduction generated
by the bootstrap replicates. In all replicates, costs per
patient were higher and mean SABP per patient was
lower in the monitored group than the control (p<0.001
for both variables). This indicates that the telemonitor-
ing was both more costly and more effective than usual
care in all replicates. The ICER was £25.60/mm Hg
(95% CI £16.05 to £46.69).
Figure 1 shows the probability of telemonitoring being
cost-effective at varied NHS willingness to pay per BP
point reduction. The 100% line represents the base case
analysis with intervention costs at £70.77 and the other
lines showing how the CEAC would change if interven-
tion costs were higher or lower.
DISCUSSION
Over the 6 months of the trial, the intervention was sig-
niﬁcantly more effective than usual care but also signiﬁ-
cantly more costly on average lowering SABP by
4.51 mm Hg and raising the total cost by £115.32. The
increase in costs was predominantly driven by the esti-
mated intervention costs (£70.77) and increased costs
associated with telemonitored patients using on average
Figure 1 Cost effectiveness acceptability curves with varied price of intervention.
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approximately one additional GP surgery consultation
and half a practice nurse surgery consultation. Although
telephone consultations with the practice nurse and
their costs also signiﬁcantly rose (by approximately half
a call on average), the costs for these were relatively
small and had little impact on total cost.
The trial found a signiﬁcant increase in the dosages of
medication issued6 which may explain some of the add-
itional consultations as they were likely to have been
required for prescribing and monitoring of patients
during transition to a new drug/dose. Interestingly,
however, medication costs did not rise signiﬁcantly in spite
of this intensiﬁcation. This is due to higher dosage pills
often costing less per dose than lower dosage pills when
costs of generic treatments are used for these estimates.16
There is a risk that the way in which the medication costs
were estimated (selecting a generic where available and
selecting the lowest cost option that matched dosing
recommendations11) could have contributed substantially
to this ﬁnding. However, such an approach does at least
attempt to estimate the difference in costs attainable
under best practice assuming this includes the selection of
the lowest cost drug based on active agent.
It should be noted that our accompanying qualitative
study27 suggests that over the trial, clinicians found
face-to-face communication with patients was not neces-
sary to support BP telemonitoring and that they substi-
tuted some of these forms of consultation with other
modes of communication: mainly telephone and on two
occasions email. Both patients and clinicians thought that
in the longer term, BP telemonitoring would reduce the
need for surgery visits. Thus, a reduction in the GP consul-
tations element of the overall costs may be realised in the
longer term. This has been found in previous studies of
telemonitoring where consultation costs were lower.28–30
The remaining cost elements were also non-signiﬁcantly
different between groups and played relatively minor roles
in the overall total cost differences.
In sensitivity analysis, hospital costs were non-
signiﬁcantly higher on average in the intervention group
than in the control by £105.47 raising differences in mean
total costs to £214.70. However, the differences in costs of
hospital admissions were exaggerated by the inclusion of
an outlier patient in the intervention arm unrelated to BP
management. With these excluded, hospital costs were
similar in both arms with an insigniﬁcant difference of
£16.56. In both cases, uncertainty surrounding hospital
cost dominated uncertainty surrounding total cost ﬁgures.
Hence, when hospital admissions are included in total
costs estimates, we are no longer conﬁdent that the cost of
resource use outside of the intervention service itself was
higher or lower in the intervention group because second-
ary care costs have the potential for the largest ﬁnancial
impact on the NHS. However, there are strong reasons to
doubt that any of the hospital admissions observed during
the trial were related to the patient’s current BP, even
those of cardiovascular nature. This is because it is possible
that the events resulting in hospital admission may well
have been set in motion prior to the onset of the study
though we lack data to conﬁrm this either way. A recent
Table 4 Estimated mean (SE) healthcare service resources used and associated costs per patient by factor
Monitored group (N=200) Control group (n=201)
Number
used Cost, £
Number
used Cost, £
Mean cost Difference,
£ (95% CI*)
p
Value*
GP consultations
Surgery consultations 3.61 (0.19) 130.00 (7.00) 2.70 (0.21) 97.11 (7.46) 32.89 (14.55 to 51.04) <0.001
Phone consultations 0.57 (0.08) 12.43 (1.78) 0.49 (0.09) 10.69 (1.98) 1.74 (−2.74 to 6.09) 0.447
Home consultations 0.06 (0.03) 7.74 (3.24) 0.09 (0.04) 10.39 (4.52) −2.65 (−11.91 to 5.27) 0.553
Total consultations 4.24 (0.23) 150.17 (8.90) 3.27 (0.27) 118.19 (10.52) 31.97 (8.38 to 54.22) 0.004
Practice nurse consultations
Surgery consultations 1.90 (0.18) 22.75 (2.11) 1.41 (0.14) 16.88 (1.71) 5.86 (1.14 to 11.00) 0.016
Phone consultations 0.69 (0.09) 3.28 (0.42) 0.15 (0.05) 0.71 (0.25) 2.57 (1.75 to 3.45) <0.001
Home consultations 0.02 (0.01) 0.41 (0.28) 0.01 (0.01) 0.30 (0.27) 0.11 (−0.38 to 0.77) 0.704
Total consultations 2.61 (0.21) 26.43 (2.27) 1.57 (0.17) 17.89 (1.88) 8.54 (3.46 to 14.15) 0.002
District nurse consultations 0.04 (0.02) 0.67 (0.41) 0.15 (0.11) 3.94 (3.05) −3.26 (−11.94 to 0.39) 0.249
NHS24 consultations 0.10 (0.03) 4.03 (1.39) 0.05 (0.02) 2.12 (0.79) 1.91 (−0.42 to 4.95) 0.139
LUCS consultations 0.07 (0.02) 4.34 (1.39) 0.04 (0.02) 2.48 (1.16) 1.86 (−0.89 to 4.83) 0.193
Medication 24.07 (2.12) 23.59 (2.20) 0.48 (−5.83 to 6.40) 0.868
Accident and emergency
visits
0.07 (0.02) 6.70 (2.24) 0.10 (0.03) 9.74 (2.98) −3.04 (−8.87 to 2.47) 0.286
Subtotal excluding
tele-monitoring
216.41 (11.66) 177.95 (15.15) 38.46 (5.59 to 69.87) 0.019
Tele-monitoring service and
device
70.77 70.77
Total healthcare costs 287.18 (11.66) 177.95 (15.15) 109.23 (76.36 to 140.63) <0.001
*p Values (two-tailed) for significant difference from zero and Bias corrected CI estimated by non-parametric bootstrap (10 000 replications).
GP, general practitioner; LUCS, Lothian Unscheduled Care Service (out of hours GP or nurse consultations); NHS, National Health Service.
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meta-analysis also found no link between home BP telemo-
nitoring and short-term rates of adverse events.28
Dividing per patient mean differences in costs by per
patient mean differences in blood-pressure reduction
yields an ICER of £25.56/mm Hg. While on the face of
it modest, there are to our knowledge no criteria avail-
able to assess the cost-effectiveness of the value of a
BP-point reduction, hence no formal assessment of
whether this constitutes evidence that the intervention is
cost-effective or not can be offered. It should also be
recognised that £25.56/mm Hg is a ratio rather than a
tariff. It is perhaps more accurate to say that over the
ﬁrst 6 months of the intervention we estimate that BP
will reduce on average by 4.51 mm Hg at a cost of
around £115.32/patient.
It is not known if the improved BP control found in the
trial would be sustained once telemonitoring ceased.
However, if sustained over 10 years, this type of reduction
would be expected to lead to a >15% reduction in risk of
stroke and >10% reduction in risk of coronary heart
Figure 2 Consort diagram.
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disease.31 The costs incurred in the intervention period
were low relative to the several thousand pounds likely to
be spent on a cardiovascular event.15 19 32 For example,
Youman et al32 calculated the cost of a stroke to the NHS
in 2001 to be £15 306 over 5 years. Should the BP-point
reduction be sustained beyond the observed 6 months
examined here, the expected reduction in cardiovascular
events31 may mean that the intervention is dominant
over usual care in the long term that is to say, both more
effective and cost saving. Estimating this would require a
study with a much longer follow-up or, perhaps more
realistically, mathematical modelling of longer term
health costs and beneﬁts. Longer term follow-up of
the participants is planned to determine the extent to
which the difference in systolic BP persists after the end
of the trial, which will be vital data to underpin such
modelling.
Strengths and limitations
Unlike many previous studies, we used ABPM to
measure BP. This is a considerable strength as ABPM is
considered the gold standard for BP measurement and
lends greater generalisability to the results as it is now a
recommended practice in the UK to diagnose high BP
with ABPM.10 The generalisability is further strength-
ened by the pragmatic setting, intention to treat analysis,
the broad socioeconomic proﬁle of participants and the
absence of restrictions on participant age (oldest patient
was 95) or exclusion on the basis of maximal treatment.
The results may be less generalisable outside of a UK
context as this is beyond the scope of this analysis.
The analysis was not part of the original trial protocol.
It was, however, conceived prior to the start of the
primary clinical analysis; the usual limitations of post
hoc analysis are less relevant. This did, however, mean
that the cost analysis was restricted by the variables avail-
able in the dataset and that some cost elements have not
have been accounted for, most notably outpatient visits.
On the other hand, the variables that were collected
were similar to those used in other trials and are likely
to be robust as surveys were completed with access to
medical records.
It was not possible to control for baseline cost in multi-
variate analysis as these were not recorded. Instead, the
analysis relies on baseline SABP and health-related
quality of life and on the randomisation process in its
place. While it is possible that a different result may
have been observed had baseline costs been available for
use, we do not anticipate that this would have differed
considerably from the results presented here as it is not
unreasonable to expect both of these factors to be
highly correlated with baseline costs. Selection bias is
very unlikely to have occurred during the randomisa-
tion/minimisation process as this service was provided
remotely by clinical trials unit.
It was not possible to determine if £25.56/mm Hg
reduced would be considered cost-effective or not.
Using the NICE criteria for cost-effectiveness, the value
of interventions is interpreted in terms of long-term cost
per quality-adjusted life-year (QALY) gained.33 34 The
EuroQol EQ-5D survey from which QALYs can be calcu-
lated22 was included in the trial.6 However, without sufﬁ-
cient power or follow-up to detect major cardiovascular
events, differences in quality of life observed in the trial
period would be unlikely to manifest themselves in an
asymptomatic condition. Moreover, given that the parti-
cipants were not blind to the intervention, this might be
open to bias. Hence, QALYs could not reliably be esti-
mated in this context. They are arguably better left to be
determined by longer term modelling.
Comparisons to similar studies
Caution is advised when comparing studies of telemoni-
toring as the services within which the telemonitoring is
nested often vary substantially and it is the combined
effect of the telemonitoring and other interrelated ser-
vices which are observed.
Two recent systematic reviews of BP telemonitoring
found few studies which included measures of health-
care utilisation and/or cost. Of those which did, ofﬁce
visits are frequently the only healthcare resource consid-
ered outside of the direct cost of the technology
issued28 35 and none were based in a UK setting, though
a UK study by McManus et al29 suggests that an accom-
panying cost-effectiveness analysis is forthcoming.
Meta-analyses of home BP telemonitoring versus usual
care by Omboni et al28 ﬁnd home BP telemonitoring to
be associated with increased medication use, reduced
ofﬁce visits and increased overall healthcare costs,
though medication use and overall healthcare casts suf-
fered from heterogeneity between studies. While the
increased prescribing is in line with our own ﬁndings, the
decreased ofﬁce visits are not. As a result, Omboni et al28
attribute the rise in healthcare costs to the cost savings in
terms of ofﬁce visits being more than offset by equipment
costs where our ﬁndings suggest an increase in both.
Figure 3 Scatter plot: incremental costs against incremental
blood pressure reduction.
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An explanation for this disparity may come from
the heterogeneity of the services being delivered
alongside the telemonitoring. For example, McManus
et al29 showed that adding a medication self-titration
plan to BP telemonitoring produced similar reduc-
tions in BP to our study, but found no increase in
face-to-face consultations with physicians. This lends
strength to the possibility that many of the increased
GP surgery visits observed in this trial were required
for prescribing.
Comparisons of healthcare costs with studies outside
of the UK can also be problematic as different social
insurance systems jeopardise cross-border generalisabil-
ity; indeed, Omboni et al28 attribute the heterogeneity in
their analysis of healthcare costs to this issue.
Madsen et al30 compared the cost-effectiveness of a
similar intervention with usual care from a Danish
health service perspective. In contrast to our ﬁndings,
they found higher consultation and medication costs in
their control arm. Again, these were more than offset by
equipment costs leaving total costs signiﬁcantly higher
in the intervention arm; however, SABP was non-
signiﬁcantly higher in the intervention arm by
2.8 mm Hg. The authors attribute the raised medication
costs to signiﬁcantly increased prescribing of
AT2-antagonists in the control arm. This intensiﬁcation
in prescribing in the usual care group rather than the
intervention group as in our trial may go some way to
explaining the lower reduction in BP observed.
However, the fact that point estimates for SAPB improve-
ment in Madsen et al’s study were still in favour of the
intervention suggests that medication prescribing may
not be the only factor inﬂuencing BP.
CONCLUSIONS
In conclusion, although more expensive to the NHS than
usual care, telemonitoring of BP in primary care was
more effective at reducing BP during the 6 months of
intervention. These costs may be recuperated in the long
term as a result of prevention of future cardiovascular
events if the reduction in BP is maintained. Further
research is required to determine if the BP improvement
is sustained and, if so, what impact this has on
cost-effectiveness.
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